Amarin Co. plc (NASDAQ:AMRN) Expected to Post FY2021 Earnings of ($0.04) Per Share

Amarin Co. plc (NASDAQ:AMRN) – Analysts at Piper Sandler decreased their FY2021 earnings per share estimates for shares of Amarin in a research report issued on Monday, January 10th. Piper Sandler analyst Y. Rahimi now anticipates that the biopharmaceutical company will post earnings per share of ($0.04) for the year, down from their previous forecast of $0.05. Piper Sandler also issued estimates for Amarin’s Q4 2021 earnings at ($0.02) EPS, Q1 2022 earnings at ($0.02) EPS, Q4 2022 earnings at $0.02 EPS and FY2022 earnings at ($0.01) EPS.

Other research analysts also recently issued reports about the company. Zacks Investment Research upgraded Amarin from a “hold” rating to a “strong-buy” rating and set a $4.00 price objective for the company in a research report on Wednesday. SVB Leerink restated a “buy” rating and set a $12.00 price objective on shares of Amarin in a research report on Sunday, September 26th. One research analyst has rated the stock with a sell rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $8.20.

AMRN stock opened at $3.52 on Thursday. The firm has a 50 day moving average of $3.60 and a 200-day moving average of $4.44. Amarin has a 12-month low of $3.11 and a 12-month high of $9.25. The company has a market cap of $1.39 billion, a price-to-earnings ratio of 85.25 and a beta of 2.13.

Amarin (NASDAQ:AMRN) last announced its quarterly earnings data on Wednesday, November 3rd. The biopharmaceutical company reported ($0.03) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.04) by $0.01. Amarin had a negative net margin of 0.34% and a positive return on equity of 1.89%. The firm had revenue of $142.00 million during the quarter, compared to the consensus estimate of $161.29 million. During the same quarter last year, the firm earned ($0.02) earnings per share. The firm’s revenue was down 8.5% compared to the same quarter last year.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. B. Riley Wealth Management Inc. grew its stake in shares of Amarin by 14.8% during the 2nd quarter. B. Riley Wealth Management Inc. now owns 19,400 shares of the biopharmaceutical company’s stock valued at $85,000 after buying an additional 2,500 shares during the period. Court Place Advisors LLC grew its stake in shares of Amarin by 32.4% during the 2nd quarter. Court Place Advisors LLC now owns 13,500 shares of the biopharmaceutical company’s stock valued at $59,000 after buying an additional 3,300 shares during the period. SG Americas Securities LLC grew its stake in shares of Amarin by 25.5% during the 2nd quarter. SG Americas Securities LLC now owns 17,184 shares of the biopharmaceutical company’s stock valued at $75,000 after buying an additional 3,497 shares during the period. Geode Capital Management LLC grew its stake in shares of Amarin by 1.2% during the 2nd quarter. Geode Capital Management LLC now owns 305,715 shares of the biopharmaceutical company’s stock valued at $1,339,000 after buying an additional 3,599 shares during the period. Finally, Geneos Wealth Management Inc. grew its stake in shares of Amarin by 3.0% during the 3rd quarter. Geneos Wealth Management Inc. now owns 134,175 shares of the biopharmaceutical company’s stock valued at $685,000 after buying an additional 3,850 shares during the period. 30.24% of the stock is owned by institutional investors.

In other news, Director Joseph S. Zakrzewski bought 10,000 shares of the stock in a transaction on Tuesday, December 14th. The stock was purchased at an average cost of $3.27 per share, with a total value of $32,700.00. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 2.67% of the stock is currently owned by insiders.

Amarin Company Profile

Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. Its product development program leverages its experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. It has developed and markets Vascepa capsules through wholesale.

Featured Story: Capital Gains

Earnings History and Estimates for Amarin (NASDAQ:AMRN)

Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.